裴氏升血颗粒配合化疗治疗急性非淋巴细胞性白血病的临床研究

Clinical Study on Pei′s Sheng Xue Granules Combined with Chemotherapy in Treating Acute Non Lymphocytic Leukemia

目的:探讨"裴氏升血颗粒"配合化疗对急性非淋巴细胞性白血病多药耐药及患者5年生存率的影响。方法:将急性非淋巴细胞性白血病患者90例随机分为3组。治疗Ⅰ组30例在DA方案化疗的同时口服升血颗粒15g,2次/d;治疗Ⅱ组30例在DA方案化疗的同时口服升血颗粒30 g,2次/d;对照组30例单纯采用DA方案化疗。结果:治疗后两治疗组测得P170表达率明显低于对照组,其差异有统计学意义(P<0.05);治疗Ⅰ组与对照组5年生存率相比,治疗Ⅰ组明显高于对照组,差异有统计学意义(P<0.05)。结论:"裴氏升血颗粒"配合化疗治疗急性非淋巴细胞性白血病可明显降低P170的表达率,并能提高患者5年生存率。

Objective： To discuss the effects of ＂Pei＇s ShengXue granules＂ combined with chemotherapy on multidrug resistance of the patients suffering from acute non lymphocytic leukemia （ANLL） and five-year survival rate of the patients. Methods： Altogether 90 patients were randomized into three groups. The treatment group I took ShengXue granules when they received chemotherapy according to DA plan, 15g, twice per day; the treatment group II ShengXue granules, 30 g, twice per day; the control group accepted chemotherapy according to DA plan only. Re- suits： P170 expression rates of the treatment groups were lower than that of the control group significantly after treating, and there was significant difference （P〈0.05）; the treatment group I was higher than the control group obviously when the treatment group I was compared with the control group in five-year survival rate, and there was significant difference （P〈0.05）. Conclusion： Pegs ShengXue granules combined with chemotherapy could obviously decrease expression rate of P 170 and raise five-year survival rate of ANLL patients.